FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [®] Kaye Edward M. MD						2. Issuer Name and Ticker or Trading Symbol Sarepta Therapeutics, Inc. [SRPT]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) 215 FIRST STREET						3. Date of Earliest Transaction (Month/Day/Year) 11/09/2016										X Offic belo	er (give title	CEO &	Other below)	(specify	
SUITE 4	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street) CAMBRIDGE MA 02142																X Form	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																					
		Tab	le I - N	lon-Deriv	ative \$	Sec	urit	ties A	cqui	ired, [Disp	osed	of, or	Bene	ficia	lly Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Exe if a	ecutio ny	eemed ition Date, th/Day/Year)		Transaction Dis Code (Instr. and			ecurities Acquired (osed Of (D) (Instr. 3 5)			Secur Bene Owne	ficially	6. Own Form: (D) or Indirec (Instr.	Direct t (I)	7. Nature of Indirect Beneficial Ownership		
									c	Code	v	Amour	nt (/	A) or D)	Price	Repo Trans	Following Reported Transaction(s) (Instr. 3 and 4)		4)	(Instr. 4)	
Common Stock 11/09/20					2016)16				М		3,0	3,000 A		\$ <mark>8</mark> .2	28 7	75,635	I)		
		Та	able II	- Derivat (e.g., p												/ Owned	I				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any (Month/Day/Year)		4. Transact Code (In 8)				Expi	6. Date Exercisabl Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own For Dire or I (I) (4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	V (A)		(D)	Date Exerc	e rcisable		iration	Title	or	ount nber res						
Incentive Stock Option (right to	\$8.28	11/09/2016			М			3,000		(1)	06/	20/2021	Commo: Stock	ⁿ 3,0	000	\$0.00	45,309		D		

Explanation of Responses:

1. This option became exercisable at the rate of 25% of the shares on June 20, 2012 and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option became fully exercisable on June 20, 2015.

Remarks:

buy)

/s/David Tyronne Howton, as Attorney-in-Fact for Edward 11/10/2016

M. Kaye

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.